1195results about "Specific peptides" patented technology

The invention discloses a human albumin binding peptide 1E3 and application of the human albumin binding peptide 1E3 in promoting purification of human albumin, and belongs to the technical field of polypeptides. The human albumin binding peptide comprises an amino acid sequence as shown in SEQ ID NO. 1; and / or an amino acid sequence of a fusion protein with the same function, which is obtained by connecting tag protein to the N terminal and / or C terminal of the amino acid sequence as shown in SEQ ID NO.1. The human albumin binding peptide has extremely high affinity with human albumin and can be used for separating and purifying a human albumin solution, and the purity of the purified human albumin far exceeds the pharmacopoeia standard and can reach 99.99% or above. The method is good in safety and stable in process, and has a wide application prospect in the aspect of separation and purification of the human albumin.

Compositions, methods and systems for targeted delivery using one or more shuttles operably linked to one or more cargos (e.g., cargo polypeptides, e.g., cargo oligonucleotides) and subsequent quantification of an abundance of one or more cargos (e.g, proteins) in a mixture (e.g., a complex mixture (e.g., in vivo)) or in a specific cell, tissue, or organ of interest (e.g., in vivo) using barcodes (e.g., peptide barcodes), binders (e.g., polypeptide binders), and binding agents (e.g., phage) are provided herein.

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.

The present disclosure provides anti-LILRB4 antibodies or antigen-binding fragments thereof, anti-LILRB4 chimeric antigen receptor proteins, isolated polynucleotides encoding them, pharmaceutical compositions comprising them, and uses thereof.

Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.

Provided herein are cell surface receptors that include an extracellular binding domain, a transmembrane domain, an intracellular signaling domain, and a protease cleavage site disposed between the extracellular binding domain and the intracellular signaling domain. In certain aspects, the cell surface receptors are engineered cell surface receptors, such as chimeric antigen receptors (CARs). Also provided are cells that include such receptors (e.g., where the cells express the receptors on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the cell surface receptors, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for regulating signaling of a cell surface receptor, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable cell-based therapy to an individual.

The present invention provides humanized antibodies and antigen-binding fragments thereof that bind to human poliovirus (PVR), which are useful in treating tumors or cancer.

The present invention includes antibodies or antigen-binding fragments thereof that specifically bind to TMPRSS2, and methods of using such antibodies and fragments to treat or prevent viral infection (eg, influenza virus infection). [Selected Figure] Figure 2

The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.

The present disclosure provides compositions and methods for primed editing of target DNA molecules (e.g., genomes), which enable the incorporation of nucleotide changes and / or targeted mutagenesis. Nucleotide changes can include single nucleotide changes (e.g., any transition or any transversion), the insertion of one or more nucleotides, or the deletion of one or more nucleotides. More specifically, the present disclosure provides a fusion protein comprising a nucleic acid programmable DNA binding protein (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA termed PEgRNA. The PEgRNA is modified to include an extended portion (relative to the standard guide RNA) that provides a DNA synthesis template sequence. This encodes a single-stranded DNA flap that is homologous to the strand of the targeted endogenous DNA sequence to be edited, but which contains the desired one or more nucleotide changes, and which becomes incorporated into the target DNA molecule after synthesis by the polymerase (e.g., reverse transcriptase). Various methods utilizing prime editing are also disclosed herein, including, among others, treating trinucleotide repeat contraction diseases, incorporating targeted peptide tags, treating prion diseases by incorporating protective mutations, engineering genes encoding RNA for the incorporation of RNA tags to control RNA function and expression, constructing high performance gene libraries using prime editing, inserting immune epitopes onto proteins using prime editing, using prime editing to insert inducible dimerization domains onto protein targets, and delivery methods.

To provide universal antigen presenting cells.SOLUTION: Also provided herein are methods of expanding immune cells using the UAPCs and methods for the treatment of a disease, such as cancer, using the expanded immune cells.SELECTED DRAWING: Figure 1A

The present disclosure relates to anti-glyco-LAMP1 antibodies and antigen-binding fragments thereof that specifically bind to cancer-specific glycosylation variants of LAMP1, as well as related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to the use of antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.

This invention provides an effective method for the delivery and stabilization of exogenous gene materials for therapeutic purposes. [Solution] A method and composition for modulating a target genome and the stable integration of a target transgene into the cellular genome are disclosed.

The present invention pertains to the technical field of biomedicine, and specifically relates to a gene delivery system and use thereof in the preparation of a tumor therapeutic drug. The present invention relates to a technical means for inducing differentiation of tumor cells into mature cells, which utilizes messenger ribonucleic acid to regulate the expression of HNF4α in tumor cells, inhibits the malignant phenotype of malignant solid tumor cells, and achieves the effect of treating malignant solid tumors, thereby being applied to a preparation method and use of a solid tumor drug.

To provide immunotherapy that prevents or minimizes the failure of immunotherapy treatment due to the emergence of antigen-loss escape mutations in cancer cells, etc. [Solution] A bispecific chimeric antigen receptor comprising (a) an antigen-specific target-directed region containing an antigen-specific single-chain Fv(scFv) fragment that binds to at least two different antigens, (b) an extracellular spacer domain, (c) a transmembrane domain, (d) at least one costimulatory domain, and (e) an intracellular signaling domain, which is to be co-expressed with a therapeutic regulatory substance such as truncated epidermal growth factor receptor (EGFRt).

The disclosure relates to the technical field of vaccine preparation, and in particular to an immune-enhancing delivery system formed by targeted antigen delivery by CCL11. The system further enhances immunogenicity by fusing a chemokine CCL11 with a corresponding antigen molecule, and adding a T2 label at a terminal of the antigen molecule. The system can be a nucleic acid vector or a fusion protein or the like to be applied to prevention and / or treatment of diseases caused by a corresponding antigen. According to the present invention, by utilizing a chemotactic binding capacity of CCL11 with a surface receptor of an immune cell such as a DC, different antigen proteins are transported to the surface of the DC, so that the efficiency of phagocytosis, processing and presentation of the DC on various antigen proteins is improved, and the effect of preventing and treating related diseases is improved.

This invention provides engineered natural killer (NK) cells and methods for producing engineered NK cells. [Solution] The present invention provides engineered natural killer (NK) cells, which are genetically modified to reduce the expression, activity, and / or signaling of the FcRγ chain in the cells. The engineered NK cells and compositions comprising the engineered NK cells are useful for treating diseases such as cancer.

The present invention relates to a recombinantly constructed protein that is useful for analytical assay, particularly for determining the presence of rhabdovirus specific antibody in biological samples obtained from individuals.More specifically, the present invention relates to a polypeptide that comprises the ectodomain of rhabdovirus glycoprotein and the heterologous multimerization domain connected to said ectodomain.In one example, there is provided a fusion protein of formula xyz (wherein x consists of or comprises the ectodomain, which may not contain furin cleavage site, y is a linker site, and z is the heterologous multimerization domain that may be selected from the group consisting of immunoglobulin sequence, coiled coil sequence, streptavidin sequence, fibritin sequence and avidin sequence).

Anti-GCC single domain antibodies (e.g., VHH domain antibodies) and chimeric antigen receptors (CARs) that bind to GCC are provided, wherein the chimeric antigen receptors (CARs) comprise the anti-GCC single domain antibody in an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain. Immune cells transduced with the disclosed CAR constructs and / or chimeric receptors can be used in cancer immunotherapy.

To provide compositions and methods for regulating protein production in target cells. [Solution] The compositions and methods disclosed herein can improve diseases associated with protein or enzyme deficiency. The present invention provides, for example, a composition comprising (a) at least one mRNA molecule that is at least partly encoding a functionally secreted polypeptide, and (b) a transport vehicle comprising lipid nanoparticles. The present invention also provides a method for treating a subject deficient in a functional polypeptide, comprising administering a composition comprising (a) at least one mRNA that is at least partly encoding the functionally secreted polypeptide, and (b) a transport vehicle comprising lipid nanoparticles, wherein after administration of the composition, the mRNA is expressed in a target cell to produce the functionally secreted polypeptide.

Disclosed herein are antibodies and antigen-binding fragments thereof that specifically bind human CD4. Also disclosed are fusion proteins comprising Paramyxoviridae glycoprotein G and CD4 antibodies for targeting and transducing cells expressing CD4. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.

Provided is an anti-BDCA2 antibody. The anti-BDCA2 antibody is capable of binding to the BDCA2 antigen with high specificity, exhibits high affinity, effectively inhibits CpG-A-stimulated secretion of IFNα and IgM by PBMCs, showing potential as a therapeutic agent for autoimmune diseases.

Provided herein are compositions, systems, kits, and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) using a composition comprising: i) a plurality of nanoparticles self-assembled from a plurality of fusion proteins comprising a) at least a portion of a ferritin protein, and b) at least a portion of an immunogenic protein comprising at least a portion of the SFTS virus Gn and / or Gc envelope glycoprotein; or ii) a polynucleotide encoding the fusion protein (e.g., an mRNA sequence present in a lipid nanoparticle).

The present disclosure relates to a method for the production of CD4 + CD4 produced by genetically modifying T cells IL-10 / CAR Provide cell populations (autologous or allogeneic single donor and allogeneic polydonor). In addition, CD4 IL-10 / CAR Methods for generating CD4 cells and for immune tolerance IL-10 / CAR Methods of using the cells to treat GvHD, cell and organ transplantation, cancer, and other autoimmune and inflammatory disorders are provided.

To provide anti-New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen-binding proteins and methods of using the same.SOLUTION: The present disclosure provides antigen-binding proteins that specifically bind to an HLA-displayed New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide, and therapeutic and diagnostic methods of using those binding proteins. The antigen-binding proteins of the present disclosure bind with a high degree of specificity to HLA-displayed NY-ESO-1 and do not bind to HLA-displayed peptides that differ by 2, 3, 4, 5, or more amino acids.SELECTED DRAWING: None

While immune checkpoint block (ICB) therapy has significantly improved outcomes for metastatic melanoma, most patients do not achieve long-term benefits. Previous studies have suggested that treatment failure is partly due to insufficient immune recognition of tumor antigens (TAs). Cancer vaccines may potentially offer a complementary approach to enhance anti-tumor immunity and act synergistically with ICIs. Novel tumor antigens shared by the majority of melanoma cells are described herein. Some of the tumor antigens described herein are derived from abnormally expressed non-mutant genomic sequences, such as intronic and intergenetic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, and vaccines derived from these tumor antigens are described. The use of tumor antigens, nucleic acids, compositions, cells, and vaccines for the treatment of melanoma is also described.

Provided are anti-Nectin-4 antibodies or antigen-binding fragments thereof, antibody conjugates comprising the same, and uses thereof in the manufacture of medicaments, particularly in the manufacture of medicaments for treating and / or preventing cancer. [Solution] Provided is an antibody or antigen-binding fragment thereof that specifically binds to Nectin-4, which comprises three heavy chain CDRs, each containing a specific sequence defined according to the Chothia numbering system, and three light chain CDRs, each containing another specific sequence defined according to the Chothia numbering system.